Qianhai

Qian Hai, Researcher, Ph.D. Supervisor, currently serves as the Director of the Office of Development Planning and Discipline Construction and the Director of the New Drug Research Center at the Institute of Pharmaceutical Sciences. His primary research areas include small molecules and peptide drugs for lowering blood sugar, anti-tumor activity, reversing tumor multidrug resistance, tumor immunity, and analgesia and anesthesia. Over the past five years, he has undertaken five national and provincial-level vertical projects and multiple school-enterprise collaborative horizontal projects. He has published over 100 papers in renowned pharmaceutical journals such as the Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, and Journal for ImmunoTherapy of Cancer. He has applied for 29 Chinese invention patents and 3 international patents, with 13 patents granted.

research interests：

Small molecules and peptide drugs in lowering blood sugar, anti-tumor activity, reversing tumor multidrug resistance, tumor immunity, and analgesia & anesthesia

(1) Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function, Immunology, 2023;

(2) Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers, Journal of Medicinal Chemistry, 2023;

(3) In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer, Journal of Medicinal Chemistry, 2022;

(4) Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P‑gp- and BCRP-Mediated Multidrug Resistance, Journal of Medicinal Chemistry, 2021;

(5) Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets: a broad-spectrum candidate for an effective antibreast cancer therapy, Journal for ImmunoTherapy of Cancer, 2021.

(1) Study on the Molecular Construction, Activity Evaluation, and Mechanism of Action of Novel Diabetes Therapeutics (GLP-1R and FFAR1 Dual Agonists)；

(2) Study on the Construction, Antitumor Activity, and Mechanism of Action of Novel Antibody-Based Antigen-Targeting Peptides and Their Drug Conjugates；

(3) Development of Novel Benzodiazepine Anesthetic Drugs;

(4) Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.

13^th SERVIER Award for Young Medicinal Chemist from the Chinese Pharmaceutical Association;

Third Level of the 333 high-level talent training project in Jiangsu Province;

Jiangsu province six talent peaks high level talent project.